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Background: Use of statins on adult patients with chronic periodontitis shows a positive effect on their
periodontal status. However, effect of locally delivered statins on periodontal treatment has not yet been
systematically analyzed. Hence, the present systematic review and meta-analysis aims to evaluate effi-
cacy of statins on treating localized periodontal intrabony defects (IBDs).
Methods: An electronic search of three databases (PubMed, Embase, and Cumulative Index to Nursing
and Allied Health Literature) between January 1, 1965 and March 1, 2016, and a hand search of peer-
reviewed journals for relevant articles were performed. Controlled randomized clinical trials (RCTs) and
prospective studies with data on comparison between adjunctive locally delivered statin use to mechan-
ical scaling and root planing (SRP) and placebo in each group, with minimum 10 participants and follow-
up period of at least 6 months, were included.
Results: Ten studies, eight RCTs and two prospective studies, were included. Each study included 15
to 105 patients between 25 and 55 years of age. Statistical results were recorded; weighted mean differ-
ence (WMD) and confidence interval (CI) were calculated; and meta-analyses were performed for defect
fill, probing depth (PD) reduction, and clinical attachment level (CAL) gain in both statin and placebo/no
treatment groups. Overall analysis of defect fill presented WMD of 1.37 mm (95% CI = 0.96 to 1.77;
P <0.0001), PD reduction presented WMD of 1.76 mm (95% CI = 1.04 to 2.47; P <0.0001), and CAL
gain presented WMD of 1.58 mm (95% CI = 0.89 to 2.28; P <0.0001). However, comparison presented
considerable heterogeneity among studies.
Conclusions: This systematic review and meta-analysis find that adjunctive use of locally delivered
statins to mechanical SRP is beneficial to increasing bone fill percentage. Improved inflammatory and
bleeding control as well as PD reduction and CAL gain are possible advantages to using these drugs in
treating patients with periodontal IBDs. J Periodontol 2017;88:357-367.
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P
eriodontitis is a chronic inflammatory and in-
fectious disease of tooth-supporting tissues
leading to both attachment loss (AL) and bone
loss (BL),1 which eventually could lead to formation
of intrabony defects (IBDs). These inflammatory con-
ditions are caused by a combination of microbial
plaque and unbalanced host immune responses2
producing proinflammatory cytokines and proteolytic-
derivative enzymes that accelerate AL and BL.3
Use of controlled-release, locally delivered anti-
microbial agents in adjunct to mechanical treatments,
especially when placed subgingivally targeting specific
microorganisms, offers favorable results in treatment of
localized periodontally destructed areas.4 According
to the American Academy of Periodontology,5 results
achieved in systematic reviews ranged between 0.25
and 0.5 mm. Antimicrobial agents such as chlorhex-
idine gluconate (CHX), minocycline (MIN), doxycy-
cline (DOX), metronidazole (MET), and tetracycline
(TCN) are selected because of their sustained release
and significant probing depth (PD) reduction or CAL
gain when used in adjunct to SRP.6
Statins were first introduced as cholesterol-lowering
drugs by inhibiting 3-hydroxy-3-methylglutaryl
coenzyme A reductase,7 interfering in the cholesterol
synthesis process in the liver, which lowers choles-
terol and decreases incidence of cardiovascular
disease. Each year they are among the most pre-
scribed and top-selling drugs in the United States,
especially in middle-aged adults.8 Statins have been
reported to also possess anti-inflammatory proper-
ties,9 antioxidative features,10 antibacterial activi-
ties,11 and pleiotropic features, such as inhibiting
release of proinflammatory mediators and matrix
metalloproteinases (MMPs).12 Due to these charac-
teristics, statins have been used for treating patients
with periodontitis,13 aiming to reduce lipopolysac-
charide (LPS)-induced MMP-1, MMP-8, and MMP-9
expressions in monocytes14 as well as expression of
MMP-9 in osteoblastic cells.15
Statins have been found to have other functions in
the oral cavity, such as inhibiting interleukin (IL)-616
and LPS-induced expression of proinflammatory
genes,17 intercellular adhesion molecule-1,18 and ni-
tric oxide synthase.19 They are also known to aid in
reduction of protein prenylation by inhibiting the me-
valonate pathway upstream of bisphosphonates in
osteoclasts, eventually affecting their normal func-
tion,20 and exhibiting positive effect on proliferation
and osteoblastic differentiation of periodontal ligament
cells as seen in an in vitro study.21 In addition, statins
have been found to stimulate bone morphogenetic
protein 2 expression,22 which results in stimulation of
osteoblast proliferation and bone formation.
Various animal studies reported success in bone
regeneration when statins were applied locally.23-26
More recently, one systematic review27 concluded
that use of statins on adult patients ‡30 years of age
with chronic periodontitis (CP) showed positive effect
on their periodontal status, and that concomitant ad-
ministration of either systemic or locally delivered sta-
tins in adjunct to non-surgical therapy may help
improve periodontal health. Results of another sys-
tematic review28 also indicated beneficial effects of
statins and their potential to improve therapeutic
effect during PD treatments. However, a lack of meta-
analysis of the effect of statins on periodontal treat-
ment has been identified. Therefore, the aim of the
current study is to evaluate efficacy of locally de-
livered statins on treating localized periodontal IBDs.
MATERIALS AND METHODS
Focused Question
How effective are locally delivered statins on treating
periodontal defects in patients with CP? This question
considers: 1) population: individuals with CP and peri-
odontal IBDs; 2) intervention: use of locally delivered
statin drugs in adjunct to mechanical scaling and root
planing (SRP); 3) comparison: statin group compared
with placebo/no treatment group; and 4) outcomes:
changes in defect depth, PD reduction, clinical at-
tachment level (CAL) gain.
Selection Criteria
Inclusion criteria were: 1) publications of domestic and
international peer-reviewed literature; 2) articles written
in English; 3) human controlled randomized clinical trials
(RCTs) and prospective studies; 4) ‡6-month follow-up;
5) ‡10 patients participating in the study; and 6) articles
reporting data on changes of defect depth, PD reduction,
and/or CAL gain. Exclusion criteria were: 1) animal
studies; 2) no definition of inclusion and/or exclusion
criteria reported; 3) no specific information of drug ad-
ministration; 4) insufficient information on adjunctive
therapy during treatment period; and 5) retrospective
cross-sectional studies, case series, or case reports.
Search Strategy
A literature search was performed at the University of
Michigan School of Dentistry, Ann Arbor, Michigan,
through hand search of peer-reviewed journals for
relevant articles and electronic search of three different
databases (PubMed, Embase, and Cumulative Index to
Nursing and Allied Health Literature [CINAHL]) be-
tween January 1, 1965 and March 1, 2016, using the
following terms for each database.
PubMed. (‘‘Hydroxymethylglutaryl CoA Reductase
Inhibitors’’[mh] OR ‘‘reductase inhibitor’’[tiab] OR
‘‘reductase inhibitors’’[tiab] OR statin[tiab] OR sta-
tins[tiab] OR atorvastatin[tiab] OR fluvastatin[tiab] OR
rosuvastatin[tiab]) AND (‘‘periodontal diseases’’[mh]
OR periodontal[tiab] OR ‘‘bone regeneration’’[mh]
OR ‘‘peri-odontology’’[tiab] OR mandible[tiab] OR
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peridontitis[tiab] OR ‘‘tooth extraction’’[tiab] OR furcation
[tiab] OR intrabony[tiab] OR ‘‘intra-bony’’[tiab] OR in-
frabony[tiab] OR ‘‘infra-bony’’[tiab] OR alveolar[tiab]).
Embase. ‘‘hydroxymethylglutaryl coenzyme a re-
ductase inhibitor’’/exp OR ‘‘reductase inhibitor’’:ab,
ti OR ‘‘reductase inhibitors’’:ab,ti OR statin*:ab,ti OR
atorvastatin:ab,ti OR fluvastatin:ab,ti OR rosuvasta-
tin:ab,ti AND (‘‘periodontal disease’’/exp OR peri-
odont*:ab,ti OR ‘‘bone regeneration’’/exp OR ‘‘peri
odontology’’:ab,ti OR mandible*:ab,ti OR ‘‘tooth
extraction’’:ab,ti OR ‘‘tooth extractions’’:ab,ti OR fur-
cation*:ab,ti OR intrabony:ab,ti OR ‘‘intra-bony’’:ab,ti
OR infrabony:ab,ti OR ‘‘infra-bony’’:ab,ti OR alveolar:
ab,ti) AND [english]/lim.
CINAHL. (MH statins OR TI statin* OR AB statin*
OR TI ‘‘reductase inhibitor*’’ OR AB ‘‘reductase in-
hibitor*’’ OR TI atorvastatin OR AB atorvastatin OR
TI fluvastatin OR AB fluvastatin OR TI rosuvastatin
OR AB rosuvastatin) AND (MH ‘‘periodontal dis-
eases’’ OR MH ‘‘bone regeneration’’ OR TI periodont*
OR AB periodont* OR TI ‘‘peri odontogy’’ OR AB
‘‘peri odontogy’’ OR TI mandible OR AB mandible
OR TI ‘‘tooth extraction*’’ OR AB ‘‘tooth extraction*’’
OR TI furcation* OR AB furcation* OR TI intrabony
OR AB intrabony OR TI ‘‘intra-
bony’’ OR AB infrabony OR TI
alveolar OR AB alveolar).
Two reviewers (NZ and MPC)
independently performed the ar-
ticle search and selection process.
They first examined the titles and
abstracts of the articles and se-
lected papers for full-text screen-
ing. Any disagreements between
reviewers were resolved through
discussion. The k value was in-
troduced to examine interexa-
miner agreement.
Data Extraction
Articles fulfilling all inclusion
criteria were selected for data
extraction (Fig. 1).
Risk of Bias (Quality)
Assessment
Criteria used to assess quality of
the selected RCTs were modi-
fied from the RCT checklist of
the Cochrane Center29 and the
Consolidated Standards of Re-
porting Trials statement,30 which
provided guidelines for the fol-
lowing parameters: 1) sequence
generation; 2) allocation con-
cealment method; 3) masking
of examiner; 4) addressing in-
complete outcome data; and 5) free of selective
outcome reporting. Degree of bias was categorized
as: 1) low risk if all criteria were met; 2) moderate risk
when only one criterion was missing; and 3) high
risk if two or more criteria were missing. Two re-
viewers (MPC and LS) assessed all included articles
independently.
Statistical Analyses
Primary outcome was defect fill and secondary out-
comes were PD reduction and CAL gain. Pooled
weighted mean difference (WMD) of defect fill, PD
reduction, and CAL gain between statin-treated group
and control group were estimated using a computer
program.‡ To avoid potential bias of combining treat-
ment outcomes of different types of statins, other
statin-treated groups, such as simvastatin (SMV), ro-
suvastatin (RSV), or atorvastatin (ATV), were pooled
as subgroup analyses. Contribution of each article
was weighed. Inverse variance weighted (IV) effects
meta-analyses of the selected studies were applied to
avoid any bias caused by methodologic differences
Figure 1.
Flow diagram of literature search and screening process.
‡ Review Manager (RevMan), Version 5.0, The Nordic Cochrane Center,
The Cochrane Collaboration, Copenhagen, Denmark.
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between studies. Forest plots were produced to
graphically represent difference in outcomes of SMV-
treated and placebo groups for all included studies
using defect site as the analysis unit. Level of sig-
nificance was set at P £0.05. Heterogeneity was
assessed with x2 test and I2 test, which ranges be-
tween 0% and 100% with lower values representing
less heterogeneity. In addition, funnel plot was used
to assess presence of publication bias. Reporting
of these meta-analyses adhered to the Preferred
Reporting Items for Systematic Review and Meta-
Analyses statement.31
RESULTS
Results of Article Selection
The search process is seen in Figure 1. The search
yielded 204 articles through PubMed, 689 articles
through Embase, and 54 articles through CINAHL
(i.e., total 947 articles). An additional article was
found manually because it was published after the
search was completed, taking the total number of
articles found to 948. Both examiners scanned all
titles and abstracts for inclusion and exclusion cri-
teria and identified 10 studies that fit the profile.32-41
After screening, examiners agreed on including all
10 studies.32-41 The k value was 0.856 with 95%
confidence interval (CI) of 0.65 to 1.00. The full-text
review k value was 1.00. Number of participants in each
study ranged between 35 and 105, with each group in
a particular study consisting of 15 to 35 individuals (20
to 60 males and 0 to 50 females; age range 25 to 55
years;mean age: 40 years). Six studies had follow-up to
6 months and four of them to 9 months.
Characteristics of Included Studies
Each study included was different than the others
(Table 1), despite seven of 10 belonging to the same
group.33-39 In 2010, Kinra et al.32 compared effects
of SMV on IBD when combined with an allograft in
a prospective study. Pradeep and Thorat33 measured
effects of SMV in treating IBD. In 2012, a study group
focused on SMV effects in treating furcation in-
volvements.34 In 2013, focus shifted from healthy to
patients with well-controlled type 2 diabetes mellitus
(DMt2)35 and smokers.36 Afterward, RSV was used
instead of SMV to calculate effectiveness of synthetic
statins.37 Results of RSV proved it to be better than SMV
and so in 2016, the same group decided to compare
RSV results with ATV in one study,38 and when adding
it to platelet-rich fibrin (PRF) and porous hydroxyap-
atite (HA) bone graft in another.39 Rath et al.40 eval-
uated effects of SMV on IL-6 levels as well as treatment
outcomes. Surve et al.41 compared outcomes of SMV
with those of ATV in another prospective study in-
cluded in this meta-analysis. All other studies33-40
were RCTs that compared outcomes with a placeboT
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group. They used custom bite blocks for repro-
ducibility and a computer-aided software program
after scanning films to aid with measurements of
defect bone fill. Surve et al.41 did not mention using
custom bite blocks, but they did use conventional
radiographs like all other studies.
Results of Meta-Analyses for Defect Fill
Seven studies32-36, 40, 41 reported data on defect fill of
sites treated with SMV and placebo/no treatment.
Two studies38, 41 reported data on defect fill of sites
treated with ATV and placebo/no treatment. Three
studies37-39 reported data on defect fill of sites treated
with RSV and placebo/no treatment. Statistical re-
sults from eight of the selected studies33-38, 40, 41
were converted into effect sizes and combined in the
meta-analysis. Two studies32, 39 used a combination
of bone graft with statins in the test group; therefore,
these two studies were excluded from themeta-analyses
due to incompatible data. WMD of defect fill was
1.07 mm (95% CI = 0.81 to 1.33; P <0.0001),
1.39 mm (95% CI = -0.25 to 3.02; P = 0.10), and
2.26 mm (95% CI = 1.29 to 3.23; P <0.0001) for SMV,
ATV, and RSV subgroups, respectively (Fig. 2).
Overall analysis presented WMD of 1.37 mm (95%
CI = 0.96 to 1.77; P <0.0001), favoring statin-treated
groups. However, comparison presented consid-
erable heterogeneity among studies; P values for x2
test presented as 0.0003, <0.00001, <0.00001,
and <0.00001 for SMV, ATV, RSV, and overall sub-
groups, respectively.
Results of Meta-Analyses for PD Reduction
Seven studies32-36, 40, 41 reported data on PD re-
duction of sites treated with SMV and placebo/no
treatment. Two studies38, 41 reported data on PD
reduction of sites treated with ATV and placebo/no
treatment. Three studies37-39 reported data on PD
reduction of sites treated with RSV and placebo/no
treatment.WMDof the eight studies included33-38, 40, 41
was 2.09 mm (95% CI = 1.05 to 3.13; P <0.0001),
0.44 mm (95% CI = -0.40 to 1.28; P = 0.30), and
2.15 mm (95% CI = 1.00 to 3.30; P <0.0001) for SMV,
ATV, and RSV subgroups, respectively (Fig. 3).
Overall analysis presented WMD of 1.76 mm (95%
CI = 1.04 to 2.47; P <0.0001), favoring statin-treated
group. However, comparison presented considerable
heterogeneity among studies; P values for x2 test pre-
sented as <0.00001, <0.0002, <0.00001, and <0.00001
for SMV, ATV, RSV, and overall subgroups, respectively.
Figure 2.
Meta-analysis for comparison of defect fill among selected studies. WMD was 1.07, 1.39, and 2.26 mm for SMV, ATV, and RSV subgroups, respectively.
Overall analysis presented WMD of 1.37 mm, favoring statin-treated groups.
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Results of Meta-Analyses for CAL Gain
Seven studies32-36 ,40, 41 reported data on CAL gain
of sites treated with SMV and placebo/no treatment.
Two studies38, 41 reported data on CAL gain of sites
treated with ATV and placebo/no treatment. Three
studies37-39 reported data on CAL gain of sites
treated with RSV and placebo/no treatment. WMD of
the eight studies included33-38, 40 ,41 was 1.71 mm
(95%CI = 0.78 to 2.64; P = 0.0003), 0.67mm (95%CI =
-0.04 to 1.38; P = 0.06), and 2.16 mm (95% CI =
0.90 to 3.42; P = 0.0008) for SMV, ATV, and RSV
subgroups, respectively (Fig. 4). Overall analysis
presented WMD of 1.58 mm (95% CI = 0.89 to 2.28;
P <0.0001), favoring statin-treated group. However,
comparison presented considerable heterogeneity
among studies; P values for x2 test presented as
<0.00001, 0.05, <0.00001, and <0.00001 for SMV,
ATV, RSV, and overall subgroups, respectively.
To investigate potential publication bias, funnel
plots of meta-analyses for comparisons of defect fill,
PD reduction, and CAL gain were demonstrated in
supplementary Figures 1 (defect fill), 2 (PD reduc-
tion), and 3 (CAL gain) in online Journal of Peri-
odontology. Due to the limited number of studies
included, funnel plot could not be directly interpreted.
However, an asymmetric plot was noted and po-
tential publication bias might exist.
Results of Risk of Bias Assessment
Results of risk of bias assessment for the included
RCTs are summarized in Table 2. Eight studies33-40
were considered to have moderate risk of bias.
DISCUSSION
In the current review, three main statins identified
among the studies included were SMV, ATV, and
RSV. SMV is a natural, mevalonic acid-derived statin,
and ATV is a synthetic, heptenoic acid-derived statin.
SMV and ATV are both lipophilic, which is why they
passively diffuse through the cell membrane and are
transported by specific carriers.42 RSV is a hydro-
philic statin that has prolonged effects compared with
other statins. It works more selectively for hepatic
cells than lipophilic statins,43 and is eight times more
potent than pravastatin, another hydrophilic statin,
and seven times more potent than ATV.44 RSV is also
found to have greater anti-inflammatory action45 and
is not significantly metabolized by cytochrome P450
enzymes like its lipophilic counterparts.46 Compared
with lipophilic statins, RSV has been found to be
Figure 3.
Meta-analysis for comparison of PD reduction among selected studies. WMD was 2.09, 0.44, and 2.15 mm for SMV, ATV, and RSV subgroups,
respectively. Overall analysis presented WMD of 1.76 mm, favoring statin-treated groups.
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superior in the reversion of coronary atherosclerotic
plaques,47 in lowering low-density lipoprotein cho-
lesterol,48, 49 and in reduction of small, dense low-
density lipoproteins.50 It has also been proved that
hydrophilic statins in general are less deadly than
lipophilic statins.51
Results obtained from this study showed statin-
treated groups having significant defect fill (WMD
of 1.37 mm), PD reduction (WMD of 1.76 mm),
and CAL gain (WMD of 1.58 mm) compared with
placebo/no treatment control groups. This can be
explained by the anti-inflammatory property that
statins possess. For example, SMV has been found to
decrease production of IL-6 and IL-8, proving anti-
inflammatory properties of statins.26 A similar finding
was also reported by Rath et al.40, where the SMV-
treated group showed mean decrease in IL-6 level
from day 0 to day 90, but not in the placebo group.
Lindy et al.13 compared treatment outcome of pa-
tients taking statins with those who did not take
statins and demonstrated that patients with peri-
odontitis who also took statin drugs had 37% fewer
pathologic periodontal pockets than those not taking
statin medication. The authors elaborated beneficial
effects of statins to be mediated by their pleiotropic
anti-inflammatory effect on periodontal tissue. Sim-
ilarly, in multiple studies by Pradeep et al.,33-35 re-
duction in bleeding index from baseline to 6 months
was obvious when using SMV as a result of its anti-
inflammatory properties.
Clinical benefits of using locally delivered statins
were compared with those of using locally delivered
antibiotics. According to the systematic review on
local anti-infective therapy by Hanes and Purvis,6
WMD for PD reduction was 0.35, 0.51, 0.06, 0.36,
0.26, and 0.21 mm for CHX, DOX gels, MET, MIN,
MIN microspheres, and TCN fibers, respectively. PD
reduction WMD for statins was 2.09, 0.44, and
2.15 mm for SMV, ATV, and RSV, respectively. For
CAL gain, WMD was 0.16, 0.34, 0.07, 0.39, -0.40,
and -0.17 mm for CHX, DOX gels, MET, MIN, MIN
microspheres, and TCN fibers, respectively. CAL
gain WMD for statins was 1.71, 0.67, and 2.16 mm
for SMV, ATV, and RSV, respectively. Range of PD
reduction and CAL gain in statins is much greater
than locally delivered antimicrobials. However, fur-
ther RCTs on statins are needed for a more definitive
comparison.
All the selected studies used locally delivered
statins instead of systemically delivered ones. This
Figure 4.
Meta-analysis for comparison of CAL gain among selected studies. WMD was 1.71, 0.67, and 2.16 mm for SMV, ATV, and RSV subgroups, respectively.
Overall analysis presented WMD of 1.58 mm, favoring statin-treated groups.
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preference was made because of their rapidly ab-
sorbed characteristic after oral administration and
their low bioavailability due to their high liver spec-
ificity.46 They were also found to be less effective
when given systemically due to their higher liver
clearance.52 The subgingival drug-delivery system
also achieves higher intrasulcular drug concentra-
tions, avoids systemic adverse effects, and attains
better patient compliance.53 Side effects from taking
statins include myopathy, myalgia, rhabdomyolysis,
and elevated liver function tests that could possibly
lead to liver damage.54 However, these adverse
events are rare when given at standard doses55 and,
to the best of the authors’ knowledge, none of the
studies using gel-form statins have yet reported
complications or adverse reactions. As for locally
delivered antibiotics, a systematic review found mild
side effects to be reported in different studies. Some
of these side effects include pain during agent place-
ment, site-specific gingival redness, gingival ab-
scesses, root sensitivity, oral candidiasis with some
TCN fiber groups, and toothache and headache with
some MIN and CHX groups.6
Other modifying factors in treating IBDs, such as
DM and smoking, were taken into consideration
in some studies. Only one selected study35 in the
current meta-analyses included patients with well-
controlled DMt2 in the RCT. However, results after
treatment showed PD reduction and bone gain sim-
ilar to patients in all other studies not including
healthy patients. This outcome was consistent with
previous findings as DM was well controlled so that
host defense cells were functioning similar to those of
healthy patients.56 Regarding smoking, Rao et al.36
included smokers in their RCT. All participants
smoked >10 cigarettes/day for more than 5 years.
Interestingly, results after treatment presented PD
reduction and bone gain similar to patients who were
not smokers. This outcome might result from the
different amounts of nicotine taken and inclusion
criteria of the study design.36
Limitations noted in the current study were: 1)
possibility of selection bias as most of the included
studies (seven of 10) were from the same study
groups;33-39 2) relatively small sample sizes of
the included studies, ranging from 15 to 35 par-
ticipants per test/control group; 3) accuracy of
measurements was not calibrated in most of the
studies, which might contribute to geometric er-
rors in IBD fill on conventional radiographs; 4)
various study designs and inclusion/exclusion
criteria among the selected studies; and 5) search
criteria involved only English-language articles.
Therefore, results of the current review should be
interpreted cautiously.T
a
b
le
2
.
R
e
s
u
lt
s
o
f
Q
u
a
lit
y
A
s
s
e
s
s
m
e
n
t
A
ft
e
r
C
o
rr
e
s
p
o
n
d
e
n
c
e
W
it
h
A
u
th
o
rs
St
ud
y
A
ut
ho
rs
Se
q
ue
nc
e
G
en
er
at
io
n
R
an
d
o
m
iz
at
io
n
M
et
ho
d
s
A
llo
ca
tio
n
C
o
nc
ea
lm
en
t
M
as
ki
ng
o
f
A
ss
es
so
r
A
ll
P
at
ie
nt
s
A
cc
o
un
te
d
fo
r
at
En
d
o
f
St
ud
y
C
le
ar
Ex
p
la
na
tio
n
o
f
W
ith
d
ra
w
al
s
R
is
k
o
f
B
ia
s
P
ra
d
ee
p
an
d
T
ho
ra
t3
3
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
P
ra
d
ee
p
et
al
.3
4
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
R
at
h
et
al
.4
0
Ye
s
R
C
T
s
Ye
s
N
o
Ye
s
Ye
s
M
o
d
er
at
e
P
ra
d
ee
p
et
al
.3
5
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
R
ao
et
al
.3
6
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
P
ra
d
ee
p
et
al
.3
7
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
P
ra
d
ee
p
et
al
.3
8
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
P
ra
d
ee
p
et
al
.3
9
Ye
s
R
C
T
s
Ye
s
Ye
s
N
o
Ye
s
M
o
d
er
at
e
J Periodontol • April 2017 Sinjab, Zimmo, Lin, Chung, Shaikh, Wang
365
CONCLUSIONS
Adjunctive use of locally delivered statins with non-
surgical periodontal treatment in IBDs shows promising
results in bone fill, reduction of inflammation and
bleeding, PD reduction, and CAL gain. These results,
compared with adjunctive use of locally delivered an-
timicrobials, were superior in PD reduction and CAL
gain. There is need for future multicenter RCTs to
warrant additional benefits of using statins in combi-
nation with non-surgical periodontal treatment for
patients with periodontitis.
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